ArticleHemaSphere2025

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade.

Thomas M Kuczmarski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.